Baxter International, Inc. (BAX) Presents Efficacy and Safety Data Evaluating GAMMAGARD LIQUID for Multifocal Motor Neuropathy at American Academy of Neurology Annual Meeting

4/27/2012 10:07:17 AM

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today announced the presentation of Phase III clinical data evaluating the safety and efficacy of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for the treatment of multifocal motor neuropathy (MMN). The data were presented during a Clinical Trials Forum at the 64th annual meeting of the American Academy of Neurology (AAN) in New Orleans, La., and formed the basis for a regulatory filing seeking an indication to treat the condition.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Baxter International, Inc.

• American Academy of Neurology

• Clinical - Phase III